rayocomp ps 1000 polar - wordpress.com...ischialgia distorsion of ankle joint cervical spine...
TRANSCRIPT
RAYONEX Schwingungstechnik GmbHSauerland-Pyramiden 1 • D-57368 Lennestadt
Phone: +49 2721/6006-0 • Fax: +49 2721/6006-66
CASE STUDIESACCORDING TO DR. MED. GERHARD BREIER
COLOGNE
Rayocomp PS 1000 polarHigh efficiency bio resonator
Case study on the RAYOCOMP PS 1000© Dr. med. Gerhard Breier, Cologne, October 1993
In an examination- and study-programme the RAYOCOMP PS 1000 was incorporated withthe question, if subtle oscillation therapy methods using resonance frequencies have ahealing impact on pathological changes. For this reason the following sectors with indicationsand case numbers were included in the therapeutical concept:( N = number of patients)
Dermatology N = 35Neurodermatitis N = 20Allergic eczema N = 10Acne N = 5
Orthopedics N = 215Coxarthrosis N = 30Lumbalgia N = 40Spondylarthrocace N = 20Occipital-Neuralgia N = 30Migraine N = 20Ischialgia N = 30Cervical spine syndrome N = 40Distorsion of ankle joint N = 5
Cancer (NPL) N = 2Osteosarcoma N = 1Alveolar-pavement ephitelium N = 1
(Only the serological immune profile was examined in the after-treatment)
Neurology N = 3Amyotrophic lateral sclerosis (ASL) N = 1Extrapyramidal syndrome (EPS) N = 1Guillain-Barre-syndrome (GBS) N = 1
Urology N = 20Cystitis N = 15Pyelitis N = 5
HNO N = 31Sinusitis. N = 20Traumatic laryngitis N = 1Bacterial laryngitis N = 5Otitis media N = 5
Rheumatology N = 21Chronic polyarthritis cP. N = 8Chronic arthrosis N = 13
Circulatory disturbance N = 27Coronary heart diseases CHD N = 5AVK IIb N = 2Ulcus venosum N = 5Cerebral circulatory disturbance N = 15
Psychiatry N = 42Depression, generally N = 12Phobia, generally N = 10Disturbed sleep, generally N = 20
Gastro-enterology N = 56Gastritis N = 20Obstipation N = 20Acute diarrhea N = 4Colitis ulcerosa N = 12
Ophthalmology N = 10Retinal circulatory disturbance N = 8Degenerative process of the macula N = 2
Pulmology N = 52Bronchial asthma N = 20Allergic asthma N = 10Rhinitis allergica N = 22
Altogether 514 patients were treated during this case study.
Every patient had been informed about the effects of the Rayocomp. Some patients wereintentionally given incomplete information to maintain the characteristics of a ”blindexperiment”. Side effects or intolerabilities did not occur in any of the cases. None of thetreatments had to be cancelled.
Between the sessions the patients were given an oral drug on a neutral carrier*1) containingthe same bio-resonance frequencies as the treatment. This led usually to a stabilization of thetherapeutical result. Interestingly enough an improvement of the state of illness was alsoascertainable if the patients were only given the drug and not treated with frequencies. Thedaily dose varied from 1 x 5 drops to 2 x 10 drops. Overdoses almost regularly led tooverreactions including symptoms of hyperactivity.
The therapy was performed with therapy cards or an indicated, unsorted combination ofcards with up to 480 frequencies. The treatment took place two times a week with normally12 applications. Only in case of artrioventricular disease the therapy had to be cancelledbecause of increasing pain, but not until after the 18th application, therefore out of theassesment. In the beginning the treatment was performed with indicated cards, respectivelyonly one card.
*1) A radionic drug is a stimulans, consisting only of energetic potentials and not of material pharmacological substances.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Therapeutical results (Part 1)© Dr. med. Breier, Cologne, October 1993
Neurodermatitis
Allergic eczema
Acne
Coxarthrosis
Lumbalgia
Spondylarthrocace
Occipital neuralgia
Migraine
Ischialgia
Distorsion of
ankle jointCervical spine syndrome
Speech
Swallowing
Pyramidal-syndrome
GBS
Cystitis
Pyelitis
Frontal sinusitis
Traumatic laryngitis
Bacterial laryngitis
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Therapeutical results (Part 2)© Dr. med. Breier, Cologne, October 1993
Otitis - media
Angina
Chronic polarthritis
Chronic arthrosis
CHD
AVD
Ulcus venosum
Cerebral circulatorydisturbance
Depressions
Phobia
Disturbed sleep
Gastritis
Obstipation
Diarrhea
Colitis ulcerosa
Retinale circulatorydisturbance
Degeneration
of the maculaBronchial asthma
Allergic asthma
Rhinititis allergica
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
First reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 1)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910
Neurod
ermatitisA
cne
Allergic eczem
a
Days
Neuro
derm
atitis, therapy card
s: 51 - 5 - 7.A
dditionally from 5th treatm
ent on 15 - 17- 31 - 32 - 34.
Acne, therap
y cards: 51 - 5 - 7- 32.
Additionally from
5th treatment on 29 - 34 - 14 - 15.
Allerg
ic eczema, therap
y cards: 51 - 5 - 7 -15 -17.
Additionally from
5th treatment on 29 -14 - 32 - 34.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
First reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 2)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910
Sp
ondylarthrocace
Lumb
algia
Coxarthrosis
Days
Occip
ital-Neuralgia
Occip
ital-Neuralg
ia, therapy card
s: 51 - 47 - 48.
Additionally from
4th treatment on 1 - 13 - 21 - 46.
Sp
ond
ylarthrocace, therap
y cards: 51 - 36 - 50.
Additionally from
3rd treatment on 46 - 21 -13 - 2.
Lumb
algia, therap
y cards: 51 - 36 - 44 - 37.
Additionally from
7th treatment on 21 - 50 - 48 - 13.
Co
xarthrosis, therap
y cards: 51 - 44 - 37 - 46.
Additionally from
7th treatment on 50 - 15 - 5.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Cervical sp
ine syndrom
e
Ischialgia
Distorsion of the ankle joint
Days
Migraine
Mig
raine, therapy card
s: 51 - 48 - 50 - 47.A
dditionally from 3rd trearm
ent on 2 - 13 - 21 - 26or 27 - 2 - 3 - 8.
Cervical sp
ine syndro
me, therap
y cards: 51 - 46 - 47 - 48.
Additionally from
3rd trearment on 41 - 50 - 36.
Ischialgia, therap
y cards: 51 - 36 - 50 - 21.
Additionally from
5th trearment on 13 - 44 - 37 - 46.
Disto
rsion o
f the ankle joint, therap
y cards: 38 -37.
Additionally from
7th trearment on 44 - 2 -3.
Course of treatm
ent (Table 3)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910
Days
Cystitis, therap
y cards: 28 - 34.
Additionally from
6th treatment on 5 - 14 - 26 or 27.
Pyelitis, therap
y cards:: 34 - 28.
Additionally from
7th treatment on 26 or 27 - 14 - 2 - 3 - 17 - 15
Course of treatm
ent (Table 4)
© D
r. med
. Breier, C
ologne, Octob
er 199390 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
12
34
56
78
910
Pyelitis
Cystitis
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 5)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910 chronic
arthrosis
Days
Chronic
polyarthritis
Chro
nic po
lyarthritis cP., therapy card
s: 51 - 50 - 34 - 21.A
dditionally from 5th treatm
ent on 43 - 42 - 45 - 44 - 37.A
dditionally from 7th treatm
ent on 5 - 15 - 17 - 34 - 31 - 30 - 32 - 20.
Chro
nic arthrosis, therap
y cards: 51 - 45 - 37 - 34.
Additionally from
5th treatment on 15 - 17 - 36 - 21 - 5.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 6)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910
Degenerative
process of
the macula
Days
Retinal
circulatoryd
isturbance
Retinal circulatory disturbance, therapy cards: 51 - 11 - 5.
Additionally from 3rd treatm
ent on 3 - 4 - 12 - 14.
Degenerative process of the m
acula, therapy cards same com
bination as above.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 7)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910 P
hobiaD
ays
Dep
ressions
Disturb
edsleep
Disturb
ed sleep
, therapy card
s: 51 - 12 - 13.A
dditionally after 1st treatment 20 - 21.
Additionally from
5th treatment on 11 - 1 - 50 - 15 - 14 - 23.
Dep
ressions, therap
y cards: 51 - 1 - 12 - 13.
Additionally after 3rd treatm
ent 50 - 20.A
dditionally after 4th treatment 26 oder 27 - 3 - 4 - 2.
Pho
bia, therap
y cards: sam
e combination as w
ith depressions
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 8)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910
Rhinititis allergicaD
ays
Allergis asthm
a
Bronchial
asthma
Allerg
ic asthma, therap
y cards: 51 - 19.
Ad
ditionally from
2nd treatm
ent on 10 - 20.A
dd
itionally from 4th treatm
ent on12 - 15 - 17 - 32 - 34.
Bro
nchial asthma, therap
y cards: 51 -19.
Ad
ditionally after 1st treatm
ent 20 - 34 - 12.A
dd
itionally after 5th treatment 10 - 17 - 32.
Ad
ditionally after 6th treatm
ent 46 - 23 - 39 - 35.A
dd
itionally after 8th treatment 16 - 30.
Rhinititis allerg
ica, therapy card
s: 51 - 10.A
dd
itionally from 2nd
treatment on 13 - 14.
Ad
ditionally from
6th treatment onh 20 - 34 - 15 -17 - 19.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 9)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910 C
erebral
circulatoryd
isturbance
Days
Coronary
heartd
iseases
Ulcus
venosum
AV
K II b
CH
D, therap
y cards: 51 - 35 - 3 - 4.
Additionally from
5th treatment on 39 - 46
Additionally from
7th treatment on 23 - 16 - 30 - 32 - 50
Ulcus veno
sum, therap
y cards: 3 - 14 -15 -17 - 34.
Additionally from
2nd treatment on 5 - 7 - 14 - 45.
Cereb
ral circ. disturb
., therapy card
s: 51 - 1 - 3 - 4 - 8 - 12.A
dditionally from 4th treatm
ent on 13 - 48 - 47.
AV
K, therap
y cards: 3 - 4 - 44.
Additionally from
4th treatment on 14 - 15.
Additionally from
7th treatment on 35 - 5.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 10)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910 D
iarrheaDays
Ob
stipation
Colitis
ulcerosa
Gastritis
Gastritis, therap
y cards: 51 - 29.
Additionally from
2nd treatment on 30 - 31.
Additionally from
5th treatment on 23 - 18 - 2.
Diarrhea, therap
y cards: 51 - 32.
Additionally from
2nd treatment on 31 - 30 - 29 - 16 - 5 - 17.
Ob
stipatio
n, therapy card
s: 51 - 32.A
dditionally from 3rd treatm
ent on33 - 31 - 30.A
dditionally from 5th treatm
ent on 15 - 17 - 50.
Co
litis ulcerosa, therap
y cards: 51 - 32.
Additionally after 3rd treatm
ent 31 - 30.A
dditionally after 5th treatment 5 - 2 - 16.
Additionally after 9th treatm
ent 14 - 15.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Course of treatm
ent (Table 11)
© D
r. med
. Breier, C
ologne, Octob
er 1993
12
34
56
78
910
Traum. laryngitis
after intubation
Days
Otitis m
edia
Bact. laryngitis
Sinusitis
Angina
Ang
ina, therapy card
s: 51 - 14.A
dditionally after 1st treatment 9 - 10 - 47 - 15 - 17 - 34 - 5.
Laryngitis, therap
y cards: 9 - 14.
Additionally after 3rd treatm
ent 5 - 3 - 4 - 15.
Otitis m
edia, therap
y cards: 51 - 8.
Additionally after 4th treatm
ent 14 - 10 - 13 - 3 - 4 - 48.
Imm
une status before and
after theR
ayocomp
treatment (Tab
le 1)©
Dr. m
ed. B
reier, Cologne, O
ctober 1993
2300
50004,3
4,841
37
233
18137
52
142
12583
66
84
41
Leucocytes
Evy
HK
Chol.
HD
L
LDL
Triyl.Lip
ase
before
after
Imm
une status before and
after theR
ayocomp
treatment (Tab
le 2)©
Dr. m
ed. B
reier, Cologne, O
ctober 1993
before
after
201000
245000
650
1140
220
350
3,4
2,9
530
850
30
70
110110
330
550
240
47060
30
70
130
Throbo-
cyres
Lymp
ho-cytes
Mono-
cytes
Granulo-
cytes
T-LyB
-Ly
Active
T-cells
T 4
T 8
NK
-cells
cyticT-cells
Here the subpopulation of lym
phocytes before and after 10 treatments w
ith the Rayocom
p was m
easured. With ephiteliom
a after lopektomie
recurrenct. General condition very good. N
o postoperative pain, vital capacity. NA
D. O
f special meaning is the increase of T4 cells from
330to 550 and of T8 cells from
240 to 470, and the imm
une competent N
K-cells increase from
60 to 130 and the cytotoxic cells, that areim
portant for the specific imm
une response, from 30 to 70. This sm
all amount of case num
bers is only useful for observation. There are furtherC
A.-patients in the therapy, but still w
ithout measurable results.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 1)
© D
r. med
. Breier, C
ologne, Octob
er 1993
Neurod
ermatitis
N =
20A
llergic Eczema
N =
10
15%
25 %
30%
20%
10%
20%
50%
20%
Only w
ith 15 % there w
aslittle efficiency, w
ith the restof the p
opulation (85%
) thetreatm
ent was d
efinitelyeffective.
Initial deterioration followed by
slight improvem
ent with 20 %
and 70 % w
ithin the range ofefficiency.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 2)
© D
r. med
. Breier, C
ologne, Octob
er 1993
20%
20%40%
20%
10%
40%
30%
15%10%
5%
20%
55%
15%
10%
40%
35%
15%
10%
60%
30%
10%
Coxartthr.N
= 30
Lumb
algiaN
= 40
Sp
ondylarthr.
N =
40O
ccipital - N
euralgiaN
= 30
Migraine
N =
20
20% are so strongly
degenerated
and m
odified
in their anatomic structure,
that recuperation is
imp
ossible.
With 10%
recurrence overyears, also p
ostoperative w
ithp
ain and restricted
mob
ility.R
egarding the severity of the
disease success in sm
allgroup
s, but nevertheless
definite.
Often com
bined
with
lumbalgie and Ischiasneuralgia
and d
egenerative, effectthinkab
le over tendinous
structures and w
ithrem
arkable success.
Occip
ital-Neuralgia and
migraine w
ith definite therap
euticalsuccess.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 3)
© D
r. med
. Breier, C
ologne, Octob
er 1993
30%
40%
10%
10%
10%45%
25%
30%
60%
40%
10%
40%
20%
30%
15%
45%
20%
IschialgiaN
= 30
Cervical sp
ine syndrom
eN
= 40
Ankle joint d
istorsionN
= 5
AS
L Sp
eechN
=1
AS
L Sw
allowing
N =
130%
chronically recurrent,b
ut good success in sm
allgroup
s.
Hard
ly any success with the
increase of mob
ility, but a
reduction of p
ain andoed
emas.
With around
50% slight im
provem
ent of speech, b
ut notstab
le, better w
ith swallow
ing. the disease is in p
rogress, thep
atients very unstable.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 4)
© D
r. med
. Breier, C
ologne, Octob
er 1993
Extra pyramidal syndrome*
Cystitis N = 15
Pyelitis N = 5
Sinusitis N = 20
GB
S N
= 1
Dep
ressionsN
= 12
Phob
iaN
= 10
Disturb
ed sleep
N =
20
20%
80%
30%
30%
30%
40% 20% 10% 10% 20%
20%
30%
20%
20%
20%
30%40%
10%
20%
*EP
S: Ind
ifferent behavior caused
psychich d
isturbance.
With d
epressions instab
le patient structure, efficiency only in a sm
all group of 30 %
%relatively stab
le, otherwise short efficiency and
recurrent, similar to p
hobia.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Traumatic laryngitisN
= 1
Bacterial laryg.
N =
5O
titis med
iaN
= 5
Angina
N =
2
10%
40%
20%
15%
15%
20%
20%
30%
15%
15%
15%
25%
20%20%
20%
30%
40%10%
20%
Otitis m
edia and
angina comp
arable form
and d
efiniteefficiency w
ithout recurrence.
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 5)
© D
r. med
. Breier, C
ologne, Octob
er 1993
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 6)
© D
r. med
. Breier, C
ologne, Octob
er 1993
25%
15%
20%
15%
Chron. p
olyarthritisN
= 8
Chron. A
rthr.N
= 13
AV
K II b
N =
2C
HD
N =
5
10%
15%
30%
20%
10%
10%
10%
10%
30%
60%
40%
30%
20%
10%
20%
Strong d
egeneration of thefingers w
ith restrictedm
obility and
pain.
Ab
out ca. 40% w
ith small or
no effect. 35 % w
ithm
oderate effect, slightly
imp
roved m
obility and
reduced
pain. N
o recurrence.D
uration of efficiencyrelatively stab
le. 25% w
ithexellent and
stable effect.
No recurrence
up to end
of Nov. 93.
Often coronary insufficiency
with d
ecomp
ensated geriatric
heart; inspite d
efinite sym
ptom
atic imp
rovement
and red
uction of the dysp
noe.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 7)
© D
r. med
. Breier, C
ologne, Octob
er 1993
30%
20%
20%
30%
20%
25%10%
40%30%
Ulcus venosum
N =
5C
erebral circ. d
isturb.
N =
15D
epressions
N =
12P
hobia
N =
10D
isturbed
sleepN
= 20
30%
20%20%
30%
30%
25%
20%
20%
10%
30%
20%
20%
Chronic system
diseases
with rep
eated recurrence,
30% ind
ifferent, 20% slight
occusion of the ulcus but no
total healing, 50 % w
ithsatisfying closure, norecurrence.
Vascular degeneration, only
in 20 % of the cases slight
symp
tomatic im
provem
entp
ossible.
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 8)
© D
r. med
. Breier, C
ologne, Octob
er 1993
20%
30%Gastritis
N =
20O
bstip
ationN
= 20
DiarrhoeN
= 4
Colitis ulzerosa
N =
12
20%
30%
20%
30%20%
30%
30%
20%
20%
30%10%
20%
20%
30%
20%
90 80 70 60 50 40 30 20 10 10 20 30 40 50 60 70 80 90+-% %
first reaction
RecuperationDeterioration
small success
Placebo
Efficien
cy with
"N" p
erson
s examin
ed (Tab
le 9)
© D
r. med
. Breier, C
ologne, Octob
er 1993
35%
30%
40%20%
20%
10%
40%
10%
30%
10%
Retinal circ. d
ist.N
= 8
Deg. of the m
aculaN
= 2
bronchial asthm
a
N =
20
Allgic asthm
aN
= 10
Allergic R
hinitisN
= 22
35%40%
30%
30%
30%
20%
30%
20%
20%
In 30% of the cxases
lasting imp
rovement of the
vision (eye charts, short-and
longsighted)
30% d
estruction of theresp
iratory passages,
degenerative, only slight
symp
tomatic im
provem
ent. 50%
with slight or good
imp
rovement also of the vital
capacity. 40%
with clear
symp
tomatic im
provem
entalso of the vital cap
acity.
A llergic rhinitis d
epend
s onallegies and
seasons. 20 %w
ithout clear effect. 30 %variab
le for the same reasons.
Rest of the p
opulation w
ithd
efinite success without
recurrence.